to safety and pharmacokinetics. With the evolution of precision medicine, biomarkers have become essential tools in early development to characterize mechanism of action, monitor biological response, and support rational dose selection. Two major types of biomarkers—exploratory and predictive—are frequently integrated into Phase 1 protocols to bridge preclinical data with clinical outcomes. This article explains how to build a biomarker strategy in Phase 1 trials, the key differences between biomarker types, and how they align with regulatory expectations.

What Is a Biomarker?

A biomarker is a measurable indicator of biological state, condition, or response. In Phase 1, biomarkers are used to:

• Assess target engagement or pathway modulation
• Monitor pharmacodynamic (PD) response
• Identify early safety or efficacy signals
• Inform dose-response relationships

Types of Biomarkers in Phase 1 Trials

1. Exploratory Biomarkers

• Used to generate hypotheses and understand biological activity
• Not yet validated or linked to clinical outcomes
• Examples: Cytokines, gene expression signatures, imaging changes

2. Predictive Biomarkers

• Used to predict response or resistance to a drug
• Typically based on known drug mechanism or prior studies
• Examples: EGFR mutations for TKIs, PD-L1 expression for immunotherapy

Why Biomarkers Matter in Phase 1

• Mechanism validation: Confirm the drug affects its intended target in humans
• Dose optimization: Support RP2D selection with PD evidence
• Risk mitigation: Identify early toxicity signals or off-target effects
• Patient stratification: Guide cohort expansion based on biomarker status

Designing a Biomarker Strategy for Phase 1

1. Define Biomarker Objectives

• Are you measuring target engagement or functional response?
• Are the markers mechanistically relevant to the drug?

2. Select the Right Biomarkers

• Choose surrogate PD markers linked to pathway activation
• Prioritize non-invasive biomarkers where possible (e.g., blood, urine)
• Ensure analytical validity: specificity, reproducibility, sensitivity

3. Align Sampling with PK/PD Profiles

• Synchronize biomarker sampling with Cmax and Tmax
• Collect longitudinal data to assess time-course effects

4. Include Exploratory Biomarkers with Mechanistic Value

• Transcriptomics, proteomics, phospho-signaling assays
• Bioinformatics may identify patterns linked to response

Examples of Biomarkers in Phase 1 Studies

1. Oncology

• Exploratory: Changes in circulating tumor DNA (ctDNA), immune cell infiltration
• Predictive: ALK rearrangements, BRAF mutations

2. Inflammation and Autoimmune Disease

• Exploratory: Cytokine profiling (IL-6, TNF-α)
• Predictive: HLA alleles, CRP levels

3. Neurology

• Exploratory: CSF biomarkers (tau, neurofilament light chain)
• Predictive: APOE genotype in Alzheimer’s disease

4. Infectious Disease and Vaccines

• Exploratory: T-cell activation markers, viral load kinetics
• Predictive: Baseline immunity, antibody titers

Regulatory Expectations

FDA

• Supports exploratory biomarkers under IND as long as they are not used for enrollment decisions
• Predictive biomarkers must be clinically validated if used for patient selection

EMA

• Expects biomarkers to be linked to mode of action or disease modulation
• Encourages qualification through EMA biomarker qualification procedures

CDSCO (India)

• Allows inclusion of biomarkers in Phase 1 for scientific insight
• Mandates ethics approval and inclusion in ICF if additional samples collected

Biomarker Sample Logistics

• Ensure validated assays are in place before trial begins
• Standardize collection kits, transport, and processing protocols
• Use central labs for high-complexity tests (e.g., flow cytometry, NGS)

Common Pitfalls and How to Avoid Them

• Overpromising exploratory markers: Avoid regulatory reliance on unvalidated assays
• Insufficient sample timing: Align with PK and PD kinetics
• Low assay sensitivity: May obscure real biological signals

Best Practices for Biomarker Integration

• Define biomarker endpoints in protocol (primary, secondary, exploratory)
• Use validated assays or define a validation plan
• Include biostatistical plans for interpreting exploratory biomarker data
• Build biomarker strategy into translational roadmap and IND briefing documents